Foamix Pharmaceuticals

Foamix has a strong in-house pipeline of drugs for dermatologic, ophthalmologic and gynecologic indications. The Company’s lead product under development is the first-in-class Topical Minocycline Foam addressing large markets in dermatology and ophthalmology. Minocycline foam demonstrated high efficacy and favorable safety in two phase II clinical studies in Acne and Impetigo patients.  Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burns as well as ophthalmic disorders.

REHOVOT, Israel and BRIDGEWATER, N.J., Sept.  20, 2019  (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will present a corporate overview and business update at the Cantor Global Healthcare Conference on Thursday, October 3, 2019 at the InterContinental New York Barclay Hotel in New York City.

Foamix Pharmaceuticals to Present at the Cantor Global Healthcare Conference

REHOVOT, Israel and BRIDGEWATER, N.J., Sept.  04, 2019  (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,398,641 covering a method of treating acne that expires in 2037.

Foamix Announces Issuance of New U.S. Patent Covering A Method of Treating Acne that Expires in 2037

Foamix has filed an NDA just this past week for FMX103 to treat patients with papulopustular rosacea, with potential approval possible in 2020.

With 2 NDAs Already Submitted To The FDA, Foamix Sets Itself Up For A Monumental Period

Foamix has two major catalysts in the second half of 2019, including a potential approval for FMX101. Unfortunately, FOMX continues to sell off ahead of these planned catalysts.

Foamix: Unjustified Sell-Off Continues Despite Upcoming Catalysts

Foamix Pharmaceuticals Ltd. (FOMX) CEO David Domzalski on Q1 2019 Results - Earnings Call Transcript

Foamix (FOMX) delivered earnings and revenue surprises of -16.67% and -67.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Foamix (FOMX) Reports Q1 Loss, Misses Revenue Estimates

Foamix Pharmaceuticals is preparing to submit FMX103's NDA for the treatment of papulopustular rosacea. Management expects to submit to the FDA around mid-year.

News for Foamix Pharmaceuticals Stock (FOMX)